Travere Therapeutics' Change in Accured Expenses rose 728.47% to $19.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.2 million, marking a year-over-year increase of 189.46%. This contributed to the annual value of -$31.1 million for FY2024, which is 225.43% down from last year.
Per Travere Therapeutics' latest filing, its Change in Accured Expenses stood at $19.7 million for Q3 2025, which was up 1,372.42% from $1.3 million recorded in Q2 2025.
In the past 5 years, Travere Therapeutics' Change in Accured Expenses ranged from a high of $19.7 million in Q3 2025 and a low of -$24.8 million during Q1 2024.
In the last 3 years, Travere Therapeutics' Change in Accured Expenses had a median value of $1.6 million in 2023 and averaged $473,000.
In the last 5 years, Travere Therapeutics' Change in Accured Expenses soared by 8,605.29% in 2021 and then slumped by 1,137.55% in 2024.
Over the past 5 years, Travere Therapeutics' Change in Accured Expenses (Quarterly) stood at $10.4 million in 2021, then crashed by 40.90% to $6.2 million in 2022, then soared by 180.17% to $17.3 million in 2023, then slumped by 55.29% to $7.7 million in 2024, then skyrocketed by 728.47% to $19.7 million in 2025.
Its Change in Accured Expenses was $19.7 million in Q3 2025, compared to $1.3 million in Q2 2025 and -$9.5 million in Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value